^
    over2years
    Glypican 3-specific Chimeric Antigen Receptor Expressed in T Cells for Patients With Pediatric Solid Tumors (GAP) (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Baylor College of Medicine | Recruiting --> Active, not recruiting | N=18 --> 10 | Trial primary completion date: Jan 2022 --> Sep 2021
    Enrollment closed • Enrollment change • Trial primary completion date
    |
    GPC3 (Glypican 3)
    |
    GPC3 positive
    |
    cyclophosphamide • fludarabine IV • GAP T cells